ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: Moreover, evinacumab decreased odds of atherosclerotic CVD [125] and, although data on fatty liver are lacking, it is likely that inhibition of ANGPTL3 might improve NAFLD.